D-1461-2019 Class II Terminated
FDA drug recall D-1461-2019 was initiated by Macleods Pharma Usa Inc on Jun 20, 2019 and is designated Class II. Reason for recall: CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products. The recall status is terminated (terminated Oct 26, 2021). Affected quantity: 145162 bottles (13,064,580 tablets).
Recall details
- Product Type
- Drugs
- Report Date
- Jul 17, 2019
- Initiation Date
- Jun 20, 2019
- Termination Date
- Oct 26, 2021
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 145162 bottles (13,064,580 tablets)
Product description
Losartan Potassium andHydrochlorothiazide Tablets 100 mg/25 mg 90 tablets, USP Rx Only, Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536 Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA NDC 33342-052-10
Reason for recall
CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
Distribution pattern
Nationwide
Code information
BLM716A Jul-19 BLM717A Jul-19 BLM719A Aug-19 BLM720A Aug-19 BLM721A Sep-19 BLM722A Sep-19 BLM723A Oct-19 BLM724A Oct-19 BLM725A Oct-19 BLM726A Nov-19 BLM802A Dec-19 BLM803A Dec-19 BLM825A Sep-21 BLM826A Sep-21 BLM827A Sep-21
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1461-2019
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026